Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces that it has publicly filed yesterday after closing of the market in Paris a registration statement on Form F-1 with the U.S.
January 20, 2021
· 7 min read